Glenmark gets USFDA nod for ADHD drug
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Glenmark Pharmaceuticals has received final approval from the US health regulator for generic version of Strattera Capsules, used in treatment of attention-deficit/hyperactivity disorder (ADHD). It has been granted final approval by the USFDA for Atomoxetine Capsules USP, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, the generic version of Strattera Capsules of Eli Lilly and Company.

http://www.moneycontrol.com/news/business/glenmark-gets-usfda-nod-for-adhd-drug-2293301.html
Preview
Like
Comment
Share